Evidence map›Paper›PMID 26450685›Full record

ArticleBMC biotechnology2015

Expression screening using a Medaka cDNA library identifies evolutionarily conserved regulators of the p53/Mdm2 pathway.

Ping Zhang, Anne Sophie Kratz, Mohammed Salama, Seham Elabd, Thorsten Heinrich, Joachim Wittbrodt, Christine Blattner, Gary Davidson

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. The Current Situation and Development Prospect of Whole-Genome Screening.International journal of molecular sciences · 2024
    Review
  3. Cells · 2023
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Ping ZhangInstitute of Toxicology and Genetics, Karlsruhe Institute of Technology, 76021, Karlsruhe, Germany. ping.zhang@ludwig.ox.ac.uk.
Anne Sophie KratzInstitute of Toxicology and Genetics, Karlsruhe Institute of Technology, 76021, Karlsruhe, Germany. annesophie.kratz@yahoo.de.
Mohammed SalamaInstitute of Toxicology and Genetics, Karlsruhe Institute of Technology, 76021, Karlsruhe, Germany. mohammed.salama@kit.edu.
Seham ElabdInstitute of Toxicology and Genetics, Karlsruhe Institute of Technology, 76021, Karlsruhe, Germany. seham.elabd@alex-mri.edu.eg.
Thorsten HeinrichDepartment of Anti-Aging Medicine, University of Tokyo, Tokyo, 113-8865, Japan. thorsten@cbcmp.icou.osaka-u.ac.jp.
Joachim WittbrodtDepartment of Developmental Biology and Physiology, University of Heidelberg, 69120, Heidelberg, Germany. jochen.wittbrodt@cos.uni-heidelberg.de.
Christine BlattnerInstitute of Toxicology and Genetics, Karlsruhe Institute of Technology, 76021, Karlsruhe, Germany. christine.blattner@kit.edu.
Gary DavidsonInstitute of Toxicology and Genetics, Karlsruhe Institute of Technology, 76021, Karlsruhe, Germany. gary.davidson@kit.edu.
Karlsruhe Institute of Technology · DEGerman Cancer Research Center · DEHeidelberg University · DELudwig Cancer Research · BEThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe p53 tumor suppressor protein is mainly regulated by alterations in the half-life of the protein, resulting in significant differences in p53 protein levels in cells. The major regulator of this process is Mdm2, which ubiquitinates p53 and targets it for proteasomal degradation. This process can be enhanced or reduced by proteins that associate with p53 or Mdm2 and several proteins have been identified with such an activity. Furthermore, additional ubiquitin ligases for p53 have been identified in recent years. Nevertheless, our understanding of how p53 abundance and Mdm2 activity are regulated remains incomplete. Here we describe a cell culture based overexpression screen to identify evolutionarily conserved regulators of the p53/Mdm2 circuit. The results from this large-scale screening method will contribute to a better understanding of the regulation of these important proteins.

methodsExpression screening was based on co-transfection of H1299 cells with pools of cDNA's from a Medaka library together with p53, Mdm2 and, as internal control, Ror2. After cell lysis, SDS-PAGE/WB analysis was used to detect alterations in these proteins.

resultsMore than one hundred hits that altered the abundance of either p53, Mdm2, or both were identified in the primary screen. Subscreening of the library pools that were identified in the primary screen identified several potential novel regulators of p53 and/or Mdm2. We also tested whether the human orthologues of the Medaka genes regulate p53 and/or Mdm2 abundance. All human orthologues regulated p53 and/or Mdm2 abundance in the same manner as the proteins from Medaka, which underscores the suitability of this screening methodology for the identification of new modifiers of p53 and Mdm2.

conclusionsDespite enormous efforts in the last two decades, many unknown regulators for p53 and Mdm2 abundance are predicted to exist. This cross-species approach to identify evolutionarily conserved regulators demonstrates that our Medaka unigene cDNA library represents a powerful tool to screen for these novel regulators of the p53/Mdm2 pathway.

Indexed as

AnimalsCell Line, TumorEvolution, MolecularGene Expression RegulationGene LibraryHumansOryziasProto-Oncogene Proteins c-mdm2Signal TransductionTumor Suppressor Protein p53MDM2 protein, humanProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53

Identifiers

PMID26450685
PMCPMC4599741
OpenAlexW1933575866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.